We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Cloned Immune Cells Cure Skin Cancer

By Biotechdaily staff writers
Posted on 30 Jun 2008
A new study describes how a patient whose skin cancer had spread throughout his body was cured and given the all clear after being injected with billions of his own immune cells.

Researchers at the Fred Hutchinson Cancer Research Center (Seattle, WA, USA) developed an in vitro method for isolating and expanding autologous CD4+ T-cell clones with specificity for the melanoma-associated antigen NY-ESO-1. More...
They then extracted immune cells from a 52-year-old patient with refractory metastatic melanoma who had not undergone any previous conditioning or cytokine treatment, and went on to replicate these cells until they had more than 5 billion of them; the cloned cells were then infused back into the patient. As soon as the cells entered the patient, they immediately began attacking the cancer, and also led to concomitant endogenous responses against other melanoma antigens, attacking all the cancer cells in the body. The treatment mediated a durable clinical remission, and two months later medical scans failed to pick up any signs of cancer in the patient. The study was published in the June 19, 2008, edition of the New England Journal of Medicine (NEJM).

"What we and others have thought might be important is that we need to give patients more of these cancer-fighting T cells which may be present in low frequency in most people,” said lead author Cassian Yee, M.D., a translational scientist at the Fred Hutchinson Cancer Research Center. "You can do that either by giving them a vaccine or, in our case, we took the cells out and grew them and gave them back to him.”

The team believes the treatment could be effective in around a quarter of skin cancer patients whose immune systems have cells that are already primed to attack their tumors; however, the researchers cautioned against undue optimism and pointed out that they had tried the same T cell approach on eight other patients, none of whom has had the same success.

"We are hoping to expand this study, but because it's very expensive and it takes several months to grow the T cells, only a very, very small number of patients would be eligible for the trial,” added Dr. Yee. "We have far more requests than we can handle and so we are primarily interested in seeing what the next step might be in improving therapy.”


Related Links:
Fred Hutchinson Cancer Research Center

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Blood Glucose Reference Analyzer
Nova Primary
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.